Ignite Creation Date:
2024-05-05 @ 5:08 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00394238
Status:
UNKNOWN
Last Update Posted:
2006-10-31
First Post:
2006-10-29
Brief Title:
Non Alcoholic Fatty Liver Disease in Rheumatoid Arthritis
Sponsor:
Shaare Zedek Medical Center
Organization:
Shaare Zedek Medical Center
Study Overview
Official Title:
None
Status:
UNKNOWN
Status Verified Date:
2006-07
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Rheumatoid arthritis is a chronic inflammatory systemic disease It has a worldwide distribution and can affect all age group The peak incidence is between fourth and sixth decade It is more prevalent in women and its prevalence in the general population in North America is between 02-15 The etiology of RA is unknown although clusters of the disease in families and high concordance in mono-zydotic twins support genetic predisposition The prevalence of fatty liver disease in patients with rheumatoid arthritis is currently unknown We wish to study the link between the two conditions by performing a son graphic imaging of the liver in a cohort of RA patients If indeed a high prevalence of NAFLD will be found in the RA patients further support will be landed for the link between inflammation and fatty liver disease These findings may also have implications regarding the management and follow up of RA patients
The validity of sonographic imaging for detection of fatty liver diseases is currently accepted On ultrasonographic fatty infiltration of the liver produces a diffuse increase in echogenicity as compared with that of the kidneys Ultrasonography has a sensitivity of 89 and a specificity of 93 in detecting steatosis and sensitivity and specificity of 77 and 89 respectively in detecting increase fibrosis
In view of all the above data we expected to find higher prevalence of fatty liver in the patients with higher inflammation markers compare with patients with lower markers
The validity of sonographic imaging for detection of fatty liver diseases is currently accepted On ultrasonographic fatty infiltration of the liver produces a diffuse increase in echogenicity as compared with that of the kidneys Ultrasonography has a sensitivity of 89 and a specificity of 93 in detecting steatosis and sensitivity and specificity of 77 and 89 respectively in detecting increase fibrosis
In view of all the above data we expected to find higher prevalence of fatty liver in the patients with higher inflammation markers compare with patients with lower markers
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None